Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
David M. Hyman(Memorial Sloan Kettering Cancer Center), José Baselga(Novartis (Switzerland)), Jason E. Faris(Royal Marsden NHS Foundation Trust), Ian Chau(Royal Marsden NHS Foundation Trust), Martin Schüler(German Cancer Research Center), Florin Sirzén(Roche (Switzerland)), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Vivek Subbiah(Sarah Cannon), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Noopur Raje(Massachusetts General Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Martina Makrutzki(Roche (Switzerland)), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Susan Frances Lasserre(Roche (Switzerland)), Maria Elena Elez-Fernandez(Universitat Autònoma de Barcelona), Eli L. Diamond(Memorial Sloan Kettering Cancer Center), Antoine Hollebecque(Institut Gustave Roussy), Manuel Hidalgo(Hospital Universitario de Fuenlabrada), Emily Chan(Royal Marsden NHS Foundation Trust), Radj Gervais(Centre François Baclesse), Jürgen Wolf(University Hospital Cologne), Maria Luisa Veronese(Roche (Switzerland)), Josep Tabernero(Deaconess Hospital)
Cited by 1,732
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k